$HALO
HALOZYME THERAPEUTICS, INC.
Runway:cash-flow +
NasdaqMarket cap: —CIK 0001159036
Upcoming catalysts
0 surfacedNo catalysts surfaced for HALO yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06689085 | Testosterone enanthate | Phase 3 | Recruiting | 2028-03-01 |
| NCT03267940 | PEGPH20 | Phase 1 | Terminated | 2019-11-11 |
| NCT02715804 | Placebo | Phase 3 | Terminated | 2019-11-04 |
| NCT02563548 | PEGPH20 | Phase 1 | Completed | 2019-03-26 |
| NCT01839487 | PEGPH20 | Phase 2 | Completed | 2018-05-01 |
| NCT02346370 | PEGylated recombinant human hyaluronidase PH20 | Phase 1 | Terminated | 2016-08-09 |
| NCT03662334 | Rapid Acting insulin with pre-treatment of rHuPH20 | Phase 4 | Completed | 2014-02-27 |
| NCT01848990 | Commercial Hylenex® recombinant (hyaluronidase human injection) | Phase 4 | Completed | 2014-02-01 |
| NCT01453153 | Gemcitabine | Phase 2 | Completed | 2014-02-01 |
| NCT01572012 | Ondansetron | Phase 1 | Completed | 2013-11-01 |
| NCT01170897 | PEGPH20 | Phase 1 | Completed | 2013-10-01 |
| NCT01526733 | Sham Injection | Phase 4 | Completed | 2012-08-01 |
| NCT00834704 | PEGPH20 | Phase 1 | Completed | 2012-06-01 |
| NCT01275131 | Insulin aspart | Phase 1 | Completed | 2011-12-01 |
| NCT01194245 | Insulin Lispro | Phase 2 | Completed | 2011-08-01 |
| NCT01194258 | Insulin Lispro | Phase 2 | Completed | 2011-08-01 |
| NCT00979875 | Recombinant human hyaluronidase PH20 (rHuPH20) | Phase 1 | Completed | 2010-02-01 |
| NCT00883558 | Insulin Lispro | Phase 2 | Completed | 2010-02-01 |
| NCT00773175 | recombinant human hyaluronidase | Phase 4 | Completed | 2009-11-01 |
| NCT00916357 | Humalog | Phase 2 | Completed | 2009-11-01 |